Prithviraj Bose

10.2k total citations
277 papers, 4.0k citations indexed

About

Prithviraj Bose is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Prithviraj Bose has authored 277 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 208 papers in Genetics, 193 papers in Hematology and 75 papers in Molecular Biology. Recurrent topics in Prithviraj Bose's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (159 papers), Acute Myeloid Leukemia Research (117 papers) and Chronic Myeloid Leukemia Treatments (99 papers). Prithviraj Bose is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (159 papers), Acute Myeloid Leukemia Research (117 papers) and Chronic Myeloid Leukemia Treatments (99 papers). Prithviraj Bose collaborates with scholars based in United States, United Kingdom and Italy. Prithviraj Bose's co-authors include Srđan Verstovšek, Steven Grant, Jörge E. Cortes, Marina Konopleva, Varsha Gandhi, Hagop M. Kantarjian, Pankit Vachhani, Yun Dai, Lucia Masárová and Naveen Pemmaraju and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Prithviraj Bose

258 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Prithviraj Bose United States	32	2.2k	1.9k	1.9k	709	634	277	4.0k
Ramón V. Tiu United States	40	3.5k 1.6×	2.0k 1.0×	2.2k 1.2×	550 0.8×	389 0.6×	159	5.0k
Daniela Cilloni Italy	33	2.7k 1.2×	1.6k 0.8×	1.6k 0.8×	848 1.2×	676 1.1×	181	4.4k
Laurent Knoops Belgium	26	1.4k 0.7×	1.9k 1.0×	1.6k 0.8×	638 0.9×	625 1.0×	53	3.4k
H. Kantarjian United States	29	2.4k 1.1×	2.1k 1.1×	995 0.5×	637 0.9×	776 1.2×	120	3.9k
Martin Höglund Sweden	37	3.4k 1.6×	1.6k 0.8×	1.5k 0.8×	1.2k 1.7×	570 0.9×	134	5.1k
Ellen K. Ritchie United States	30	2.4k 1.1×	1.2k 0.6×	1.4k 0.7×	678 1.0×	461 0.7×	172	3.6k
Dale L. Bixby United States	27	1.6k 0.8×	864 0.5×	1.1k 0.6×	756 1.1×	331 0.5×	135	3.2k
Stefan Faderl United States	26	2.0k 0.9×	1.7k 0.9×	1.2k 0.6×	548 0.8×	279 0.4×	115	3.6k
Philipp le Coutre Germany	33	3.5k 1.6×	2.7k 1.4×	867 0.5×	831 1.2×	1.8k 2.8×	157	4.8k
Nicoletta Testoni Italy	35	3.7k 1.7×	1.9k 1.0×	1.5k 0.8×	744 1.0×	1.0k 1.6×	187	4.4k

Countries citing papers authored by Prithviraj Bose

Since Specialization

Citations

This map shows the geographic impact of Prithviraj Bose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prithviraj Bose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prithviraj Bose more than expected).

Fields of papers citing papers by Prithviraj Bose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prithviraj Bose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prithviraj Bose. The network helps show where Prithviraj Bose may publish in the future.

Co-authorship network of co-authors of Prithviraj Bose

This figure shows the co-authorship network connecting the top 25 collaborators of Prithviraj Bose. A scholar is included among the top collaborators of Prithviraj Bose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prithviraj Bose. Prithviraj Bose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vachhani, Pankit, Ruben A. Mesa, John Mascarenhas, et al.. (2025). JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. Haematologica.

Duan, Minghui, Prithviraj Bose, Anthony M. Hunter, et al.. (2025). Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera. Current Hematologic Malignancy Reports. 20(1). 13–13.

Gangat, Naseema, James M. Foran, Anna B. Halpern, et al.. (2024). A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia. Blood. 144(Supplement 1). 657–657. 3 indexed citations

Bose, Prithviraj, Hsin‐An Hou, Wojciech Homenda, et al.. (2024). Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 483–483. 3 indexed citations

Mascarenhas, John, Raajit K. Rampal, Prithviraj Bose, et al.. (2024). Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.. Journal of Clinical Oncology. 42(16_suppl). TPS6594–TPS6594. 1 indexed citations

Vachhani, Pankit, et al.. (2024). Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.. Journal of Clinical Oncology. 42(16_suppl). 6578–6578.

Watts, Justin M., Alessandro M. Vannucchi, Anthony M. Hunter, et al.. (2024). Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.. Journal of Clinical Oncology. 42(16_suppl). 6576–6576. 1 indexed citations

Arora, Sankalp, Jayastu Senapati, Lucia Masárová, et al.. (2024). Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).. Journal of Clinical Oncology. 42(16_suppl). 6572–6572. 1 indexed citations

Bose, Prithviraj, Yesid Alvarado, Gautam Borthakur, et al.. (2024). Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. PubMed. 1(2). 100008–100008. 3 indexed citations

10.

Oh, Stephen T., Ruben A. Mesa, Claire Harrison, et al.. (2023). Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Advances. 7(19). 5835–5842. 39 indexed citations

11.

Bose, Prithviraj, Stephen T. Oh, Brian D. Modena, et al.. (2023). Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood. 142(Supplement 1). 77–77. 3 indexed citations

12.

Thompson, Philip A., Michael J. Keating, Alessandra Ferrajoli, et al.. (2023). Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. Leukemia. 37(7). 1444–1453. 2 indexed citations

13.

Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2023). The role of therapy in the outcome of patients with myelofibrosis. Cancer. 129(18). 2828–2835. 3 indexed citations

14.

DeAngelo, Daniel J., Deepti Radia, Tracy I. George, et al.. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine. 27(12). 2183–2191. 88 indexed citations

15.

Mughal, Tariq I., Naveen Pemmaraju, Bethan Psaila, et al.. (2020). Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematological Oncology. 38(5). 654–664. 1 indexed citations

16.

Sasaki, Koji, Hagop M. Kantarjian, Tapan M. Kadia, et al.. (2019). Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia. Cancer. 125(21). 3755–3766. 36 indexed citations

17.

Strati, Paolo, Feng Wang, Francesco Paolo Tambaro, et al.. (2019). The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. British Journal of Haematology. 187(1). e1–e4. 1 indexed citations

18.

Gotlib, Jason, Deepti Radia, Daniel J. DeAngelo, et al.. (2018). Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood. 132(Supplement 1). 351–351. 10 indexed citations

19.

Rozovski, Uri, David Harris, Ping Li, et al.. (2017). Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex. Molecular Cancer Research. 15(5). 610–618. 23 indexed citations

20.

Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2017). Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib. Blood. 130. 201–201. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact